AZNAcerta Pharma BVRunning, no new patients
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Chronic Lymphocytic Leukemia
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 60 (final count)
- Started
- Mar 8, 2016
- Main results expected
- Oct 16, 2020
- Fully finished
- Jun 6, 2026
- Results posted
- Feb 9, 2022
What counts as success
The trial's main goal(s), called the “primary outcome.”
The Overall Response Rate (ORR) of ACP-196 (Acalabrutinib)
Measured over: From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 4 years and 7 months). 1 cycle = 28 days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02717611 · record last updated 2026-03-25 · checked 2026-11-09 15:47 UTC